JP2020511438A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511438A5 JP2020511438A5 JP2019548301A JP2019548301A JP2020511438A5 JP 2020511438 A5 JP2020511438 A5 JP 2020511438A5 JP 2019548301 A JP2019548301 A JP 2019548301A JP 2019548301 A JP2019548301 A JP 2019548301A JP 2020511438 A5 JP2020511438 A5 JP 2020511438A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- compound according
- peaks
- compound
- xrpd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SPQOYTHUHVSPOH-UHFFFAOYSA-N COc1cc(OC)c(CN(Cc2c3c(Nc(cc4)ccc4C(N4CCCC4)=O)cc(-c(c(F)ccc4)c4F)n2)C3=O)cc1 Chemical compound COc1cc(OC)c(CN(Cc2c3c(Nc(cc4)ccc4C(N4CCCC4)=O)cc(-c(c(F)ccc4)c4F)n2)C3=O)cc1 SPQOYTHUHVSPOH-UHFFFAOYSA-N 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022164799A JP7535086B2 (ja) | 2017-03-08 | 2022-10-13 | Ｔｙｋ２阻害剤、使用およびその製造のための方法 |
| JP2024127741A JP2024153877A (ja) | 2017-03-08 | 2024-08-02 | Ｔｙｋ２阻害剤、使用およびその製造のための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762468688P | 2017-03-08 | 2017-03-08 | |
| US62/468,688 | 2017-03-08 | ||
| PCT/US2018/021265 WO2018165240A1 (en) | 2017-03-08 | 2018-03-07 | Tyk2 inhibitors, uses, and methods for production thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022164799A Division JP7535086B2 (ja) | 2017-03-08 | 2022-10-13 | Ｔｙｋ２阻害剤、使用およびその製造のための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020511438A JP2020511438A (ja) | 2020-04-16 |
| JP2020511438A5 true JP2020511438A5 (https=) | 2021-04-15 |
| JP7160824B2 JP7160824B2 (ja) | 2022-10-25 |
Family
ID=63446346
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019548301A Active JP7160824B2 (ja) | 2017-03-08 | 2018-03-07 | Ｔｙｋ２阻害剤、使用およびその製造のための方法 |
| JP2022164799A Active JP7535086B2 (ja) | 2017-03-08 | 2022-10-13 | Ｔｙｋ２阻害剤、使用およびその製造のための方法 |
| JP2024127741A Pending JP2024153877A (ja) | 2017-03-08 | 2024-08-02 | Ｔｙｋ２阻害剤、使用およびその製造のための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022164799A Active JP7535086B2 (ja) | 2017-03-08 | 2022-10-13 | Ｔｙｋ２阻害剤、使用およびその製造のための方法 |
| JP2024127741A Pending JP2024153877A (ja) | 2017-03-08 | 2024-08-02 | Ｔｙｋ２阻害剤、使用およびその製造のための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10336752B2 (https=) |
| EP (2) | EP3592746B1 (https=) |
| JP (3) | JP7160824B2 (https=) |
| CN (1) | CN110582501B (https=) |
| AR (1) | AR111233A1 (https=) |
| AU (3) | AU2018230737B2 (https=) |
| CA (1) | CA3055209A1 (https=) |
| IL (1) | IL269036B2 (https=) |
| TW (3) | TW202515876A (https=) |
| WO (1) | WO2018165240A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI788655B (zh) | 2015-02-27 | 2023-01-01 | 美商林伯士拉克許米公司 | 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途 |
| TWI707852B (zh) | 2015-09-02 | 2020-10-21 | 美商林伯士拉克許米公司 | Tyk2 抑制劑及其用途 |
| EP3528816A4 (en) * | 2016-10-21 | 2020-04-08 | Nimbus Lakshmi, Inc. | TYK2 INHIBITORS AND USES THEREOF |
| SI3658557T1 (sl) | 2017-07-28 | 2024-10-30 | Takeda Pharmaceutical Company Limited | Zaviralci TYK2 in njihova uporaba |
| AR117398A1 (es) | 2018-03-12 | 2021-08-04 | Abbvie Inc | Inhibidores de la señalización mediada por tirosina cinasa 2 |
| CN113271940A (zh) | 2018-10-15 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
| JP7631193B2 (ja) | 2018-10-22 | 2025-02-18 | アルミス インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| JP2022519696A (ja) * | 2019-02-07 | 2022-03-24 | ベンティックス バイオサイエンシーズ，インク． | Ｔｙｋ２偽キナーゼリガンド |
| CA3134814A1 (en) | 2019-03-26 | 2020-10-01 | Ventyx Biosciences, Inc. | Tyk2 pseudokinase ligands |
| US11357775B2 (en) | 2019-04-30 | 2022-06-14 | Celgene Corporation | Combination therapies comprising apremilast and Tyk2 inhibitors |
| SG11202112043PA (en) * | 2019-04-30 | 2021-11-29 | Celgene Corp | Combination therapies comprising apremilast and tyk2 inhibitors |
| JP7635228B2 (ja) | 2019-11-08 | 2025-02-25 | ベンティックス バイオサイエンシーズ，インク． | Ｔｙｋ２偽キナーゼリガンド |
| EP4404930A1 (en) * | 2021-09-23 | 2024-07-31 | Bristol-Myers Squibb Company | Methods of treating hair-loss disorders with tyk2 inhibitors |
| EP4423086A1 (en) | 2021-10-25 | 2024-09-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
| WO2023183910A1 (en) * | 2022-03-25 | 2023-09-28 | Nimbus Lakshmi, Inc. | Solid forms of tyk2 inhibitors and methods of use |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4983612A (en) * | 1989-10-05 | 1991-01-08 | American Home Products Corporation | Antihypertensive benzopyran derivatives |
| DE4343923A1 (de) * | 1993-12-22 | 1995-06-29 | Basf Ag | Pyridin-2,3-dicarbonsäureimide, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung unerwünschten Pflanzenwuchses |
| DE60037345T2 (de) | 1999-12-10 | 2008-11-13 | Pfizer Products Inc., Groton | Pyrrolo(2,3-d)pyrimidin-Verbindungen |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| DE60217322T2 (de) | 2001-04-27 | 2007-10-04 | Zenyaku Kogyo K.K. | Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| PT1536827E (pt) | 2002-08-14 | 2009-03-20 | Silence Therapeutics Ag | Utilização de proteína cinase n beta |
| AU2003291021A1 (en) * | 2002-11-18 | 2004-06-15 | The Regents Of The University Of California | Arylpyridine compounds |
| AU2004228668B2 (en) | 2003-04-03 | 2011-10-27 | Park Funding, Llc | PI-3 kinase inhibitor prodrugs |
| ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| EP1692153A4 (en) | 2003-07-03 | 2007-03-21 | Univ Pennsylvania | INHIBITION OF EXPRESSION OF SYK-KINASE |
| WO2005113556A1 (en) | 2004-05-13 | 2005-12-01 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| AU2006206458B2 (en) | 2005-01-19 | 2012-10-25 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| PL1888550T3 (pl) | 2005-05-12 | 2014-12-31 | Abbvie Bahamas Ltd | Promotory apoptozy |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| US7989622B2 (en) | 2005-10-07 | 2011-08-02 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors and methods of their use |
| JP5191391B2 (ja) | 2005-11-01 | 2013-05-08 | ターゲジェン インコーポレーティッド | キナーゼのビ−アリールメタ−ピリミジン阻害剤 |
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| WO2007129161A2 (en) | 2006-04-26 | 2007-11-15 | F. Hoffmann-La Roche Ag | Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor |
| DK2526933T3 (en) | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| KR101566840B1 (ko) | 2007-03-12 | 2015-11-06 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 페닐 아미노 피리미딘 화합물 및 이의 용도 |
| WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| HUE029767T2 (en) | 2008-03-11 | 2017-04-28 | Incyte Holdings Corp | JAK inhibitor azetidine and cyclobutane derivatives |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| WO2012085168A1 (en) * | 2010-12-22 | 2012-06-28 | Ludwig-Maximilians-Universität München | Organozinc complexes and processes for making and using the same |
| WO2012097479A1 (en) * | 2011-01-21 | 2012-07-26 | Abbott Laboratories | Bicyclic inhibitors of anaphastic lymphoma kinase |
| EP3040336B1 (en) | 2012-03-02 | 2020-04-08 | Sareum Limited | Compounds for use in treating tyk2 kinase mediated conditions |
| BR112014029310A2 (pt) * | 2012-05-24 | 2018-06-26 | Cellzome Ltd | análogos da pirimidina heterocíclica como inibidores da tyk2 |
| KR102233252B1 (ko) | 2012-11-08 | 2021-03-26 | 브리스톨-마이어스 스큅 컴퍼니 | ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물 |
| LT3495358T (lt) | 2012-11-08 | 2022-05-25 | Bristol-Myers Squibb Company | Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai |
| ES2702126T3 (es) | 2013-12-10 | 2019-02-27 | Bristol Myers Squibb Co | Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa |
| WO2015131080A1 (en) | 2014-02-28 | 2015-09-03 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| TWI788655B (zh) * | 2015-02-27 | 2023-01-01 | 美商林伯士拉克許米公司 | 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途 |
| TWI707852B (zh) | 2015-09-02 | 2020-10-21 | 美商林伯士拉克許米公司 | Tyk2 抑制劑及其用途 |
| US10323036B2 (en) | 2016-10-14 | 2019-06-18 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
| EP3528816A4 (en) | 2016-10-21 | 2020-04-08 | Nimbus Lakshmi, Inc. | TYK2 INHIBITORS AND USES THEREOF |
-
2018
- 2018-03-07 TW TW113147070A patent/TW202515876A/zh unknown
- 2018-03-07 EP EP18764569.2A patent/EP3592746B1/en active Active
- 2018-03-07 CA CA3055209A patent/CA3055209A1/en active Pending
- 2018-03-07 AR ARP180100523A patent/AR111233A1/es unknown
- 2018-03-07 TW TW107107562A patent/TWI783978B/zh active
- 2018-03-07 TW TW111146722A patent/TWI868528B/zh active
- 2018-03-07 US US15/914,074 patent/US10336752B2/en active Active
- 2018-03-07 JP JP2019548301A patent/JP7160824B2/ja active Active
- 2018-03-07 WO PCT/US2018/021265 patent/WO2018165240A1/en not_active Ceased
- 2018-03-07 CN CN201880028375.5A patent/CN110582501B/zh active Active
- 2018-03-07 EP EP24153142.5A patent/EP4338802A3/en active Pending
- 2018-03-07 IL IL269036A patent/IL269036B2/en unknown
- 2018-03-07 AU AU2018230737A patent/AU2018230737B2/en active Active
-
2019
- 2019-05-21 US US16/417,901 patent/US11040967B2/en active Active
-
2022
- 2022-10-13 JP JP2022164799A patent/JP7535086B2/ja active Active
- 2022-10-19 AU AU2022256121A patent/AU2022256121A1/en not_active Abandoned
-
2024
- 2024-08-02 JP JP2024127741A patent/JP2024153877A/ja active Pending
- 2024-08-07 AU AU2024205575A patent/AU2024205575A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020511438A5 (https=) | ||
| JP2022509260A5 (https=) | ||
| US10479793B2 (en) | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | |
| US11919906B2 (en) | Crystal form of ACP-196 and method of treatment thereof | |
| IL271999B2 (en) | Tyk2 inhibitors and uses thereof | |
| JP2018537501A5 (https=) | ||
| JP2019515952A5 (https=) | ||
| TW201617319A (zh) | （２ｓ，３ｓ）７－氟－２－（４－氟苯基）－３－（１－甲基－１ｈ－１，２，４－三唑－５－基）－４－側氧基－１，２，３，４－四氫喹啉－５－羧酸甲酯之共形成體鹽及其製備方法 | |
| JP2018505199A (ja) | （Ｓ）−５−ベンジル−Ｎ−（５−メチル−４−オキソ−２，３，４，５テトラヒドロベンゾ［ｂ］［１，４］オキサゼピン−３−イル）−４Ｈ−１，２，４−トリアゾール−３−カルボキサミドの結晶形 | |
| JP2015516968A5 (https=) | ||
| JP2017508733A5 (https=) | ||
| CN113474319A (zh) | 卤化丁烯化合物的制造方法 | |
| WO2020208592A1 (en) | Process for preparation of erdafitinib, its purification and amorphous solid dispersion | |
| WO2022223027A1 (zh) | Tolebrutinib晶型、无定型及其制备方法和用途 | |
| JP2019504033A (ja) | 選択的なｓ１ｐ１受容体アゴニストの新規な結晶形及びその製造方法 | |
| WO2014174846A1 (ja) | 固形医薬組成物 | |
| MA40480B1 (fr) | Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie | |
| US20160362391A1 (en) | Improved Process for the Preparation of Pomalidomide and its Purification | |
| TWI799431B (zh) | RORγ抑制劑 | |
| JPWO2014174848A1 (ja) | 錠剤 | |
| CN111712486B (zh) | 卡利拉嗪盐酸盐的晶型及其制备方法及其用途 | |
| WO2009111061A1 (en) | Process for the preparation of sorafenib and salts thereof | |
| TWI360533B (en) | Process for the preparation of intermediates | |
| CA2465043A1 (en) | Novel mandelate salts of substituted tetracyclic tetrahydrofuran derivatives | |
| CN113272268B (zh) | 环丁烷的制造方法 |